{"schemaVersion":1,"profileUrl":"https://nowen.ai/agents/derekcroote-com","markdownUrl":"https://nowen.ai/agents/derekcroote-com.md","jsonUrl":"https://nowen.ai/agents/derekcroote-com.json","name":"IgGenix","website":"https://www.derekcroote.com","industry":"Biotechnology","status":{"trust":"unclaimed","text":"Unclaimed: compiled by Nowen from public sources, not reviewed by the company"},"updatedAt":"2026-09-06T23:15:32.979Z","summary":"IgGenix is a clinical-stage biotech company developing antibody therapies to treat allergies.","description":"IgGenix is a clinical-stage biotechnology company focused on discovering and developing antibody-based therapies to treat allergies. Led by experienced biotech leaders, the company seeks to translate scientific research into transformative treatments that improve the health and well-being of individuals affected by allergic conditions. IgGenix emphasizes scientific rigor, collaboration, and patient impact as it advances its internal programs through clinical development.","mission":"IgGenix's mission is to develop transformational antibody therapies that improve the health and quality of life for people living with allergies.","directory":{"industryName":"Biotechnology","agentCount":9,"indexable":false,"hubUrl":"https://nowen.ai/industry/biotechnology"},"aiReaderFamilies":["Anthropic","Perplexity","Amazon"],"products":[{"name":"IGNX001","type":"Product","url":"https://iggenix.com/pressreleases/iggenix-announces-first-patient-dosed-in-phase-1-clinical-trial-accelerate-peanut-evaluating-ignx001-in-peanut-allergy/","summary":"Transformative antibody therapeutic for peanut allergy, completed Phase 1 trial.","description":"IGNX001 is IgGenix's internally developed antibody therapeutic for peanut allergy. It is designed to provide a transformative solution for individuals suffering from this condition and completed a Phase 1 clinical trial in November 2025.","pricing":{},"features":[{"name":"Phase 1 completion","value":"Achieved Phase 1 Clinical Trial","valueDescription":"Successfully completed initial human trials, demonstrating its potential efficacy and safety for treating peanut allergies."}]}],"audiences":[],"segments":[{"name":"Peanut allergy therapeutics","description":"Therapies specifically designed to prevent or reduce allergic reactions to peanuts, including monoclonal antibodies and targeted immunotherapies aimed at desensitization and protection from anaphylaxis.","size":1.15,"cagr":16.9,"color":1,"productNames":["IGNX001"],"methodology":"Estimate anchored to market-research figures for the peanut-allergy vaccine/therapeutics segment: Coherent Market Insights reports a peanut allergy vaccine market of USD 1.15B in 2026 with a 16.9% CAGR (2026–2033). That vaccine/immunotherapy-focused projection is corroborated by a LinkedIn-sourced market note (~USD 1.2B in 2026; ~15.5% CAGR) and a MeditechInsights statement of ~12% near-term growth for the broader peanut allergy treatment market. SphericalInsights shows the broader allergy therapeutics market at USD 23.1B (2023), indicating peanut-specific therapeutics are a smaller, rapidly growing subsegment driven by immunotherapies and biologics.","citations":[{"url":"https://www.coherentmarketinsights.com/market-insight/peanut-allergy-vaccine-market-121","text":"Global Peanut Allergy Vaccine Market size is estimated at USD 1.15 billion in 2026; CAGR of 16.9% from 2026 to 2033."},{"url":"https://www.linkedin.com/pulse/north-america-peanut-allergy-therapeutics-market-size-ixhnc/","text":"Global Peanut Allergy Therapeutics market valued at USD 1.2 Billion in 2026; CAGR ~15.5% (2026–2033)."},{"url":"https://meditechinsights.com/peanut-allergy-treatment-market","text":"The global peanut allergy treatment market size is set to witness a growth rate of 12% in the next 5 years."},{"url":"https://www.sphericalinsights.com/reports/allergy-therapeutics-market","text":"Global Allergy Therapeutics Market size was valued at USD 23.1 Billion in 2023; CAGR 6.29% (2023–2033)."}]},{"name":"Clinical-stage antibody therapeutics","description":"Monoclonal antibody candidates undergoing clinical development for immune-mediated conditions, with emphasis on clinical safety, efficacy, and advancement through Phase 1–3 trials.","size":311.2,"cagr":7.5,"color":2,"productNames":["IGNX001"],"methodology":"Used published market forecasts for the broader antibody/monoclonal antibody therapeutics market as the addressable market for clinical‑stage antibody candidates. Primary proxy is MarketsandMarkets (USD 311.2B in 2026; 7.5% CAGR). Other sources show a range (Coherent ~USD 331.8B in 2026, BioSpace USD 233.2B in 2024, PrecedenceResearch USD 973.6B in 2024), so a conservative CAGR (7.5%) and the MarketsandMarkets 2026 market size were used as the baseline for clinical‑stage antibody therapeutics’ near‑term market potential.","citations":[{"url":"https://www.marketsandmarkets.com/Market-Reports/antibody-therapeutics-market-178852478.html","text":"$311.2B MARKET SIZE, 2026; CAGR (2026-2035): 7.5%"},{"url":"https://www.coherentmarketinsights.com/market-insight/monoclonal-antibody-therapeutics-market-2403","text":"valued at USD 331.81 Bn in 2026; CAGR of 12.9% (2026–2033)"},{"url":"https://www.biospace.com/monoclonal-antibody-therapeutics-market-size-to-reach-usd-919-06-billion-by-2033-propelled-by-pioneering-innovations-in-biopharmaceutical-engineering","text":"USD 233.19 billion in 2024; CAGR of 14.7% between 2024 and 2033"},{"url":"https://www.precedenceresearch.com/antibody-therapy-market","text":"valued at USD 973.6 billion in 2024; CAGR of 12% through 2034"}]},{"name":"Biopharmaceutical partnering and licensing","description":"Opportunities for licensing, co-development, and strategic partnerships around clinical-stage biologic assets to accelerate development, manufacturing, and commercialization.","size":15,"cagr":9,"color":3,"productNames":["IGNX001"],"methodology":"Estimate based on the overall biopharmaceutical market scale and growth (persistence market research), observed annual licensing revenues from academia (NCBI/PMC) and representative deal economics (PharmExec). Using the $515.8B biopharma market (2025) as context and university licensing revenue (~$6B) plus frequent multi‑million upfronts and multi‑hundred‑million-to‑billion milestone structures in industry deals, partnering and licensing of clinical‑stage biologics is estimated as a multi‑billion annual market (approx. 2–3% of total biopharma market). Growth potential is aligned with the broader biopharma CAGR (8–10%), reflecting increasing strategic collaborations and biologics dealmaking.","citations":[{"url":"https://www.persistencemarketresearch.com/market-research/biopharmaceutical-market.asp","text":"The global biopharmaceutical market size is valued at US$515.8 billion in 2025 and projected to reach US$910.7 billion; CAGR 8.5%."},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC4355252/","text":"Combined revenues from licensing and industry-supported research in all fields reaching well over $6 billion per year (AUTM 2012)."},{"url":"https://www.pharmexec.com/view/roundup-biotech-strategic-partnerships-exclusive-licensing-agreements","text":"Manifold Bio will receive an upfront fee of $55 million and eligibility for milestones valued upwards of $2 billion."}]}],"faq":[],"comparisons":[],"sources":[{"url":"https://www.derekcroote.com","text":"IgGenix"},{"url":"https://iggenix.com/pressreleases/iggenix-announces-first-patient-dosed-in-phase-1-clinical-trial-accelerate-peanut-evaluating-ignx001-in-peanut-allergy/","text":"IGNX001"},{"url":"https://www.coherentmarketinsights.com/market-insight/peanut-allergy-vaccine-market-121","text":"Global Peanut Allergy Vaccine Market size is estimated at USD 1.15 billion in 2026; CAGR of 16.9% from 2026 to 2033."},{"url":"https://www.linkedin.com/pulse/north-america-peanut-allergy-therapeutics-market-size-ixhnc/","text":"Global Peanut Allergy Therapeutics market valued at USD 1.2 Billion in 2026; CAGR ~15.5% (2026–2033)."},{"url":"https://meditechinsights.com/peanut-allergy-treatment-market","text":"The global peanut allergy treatment market size is set to witness a growth rate of 12% in the next 5 years."},{"url":"https://www.sphericalinsights.com/reports/allergy-therapeutics-market","text":"Global Allergy Therapeutics Market size was valued at USD 23.1 Billion in 2023; CAGR 6.29% (2023–2033)."},{"url":"https://www.marketsandmarkets.com/Market-Reports/antibody-therapeutics-market-178852478.html","text":"$311.2B MARKET SIZE, 2026; CAGR (2026-2035): 7.5%"},{"url":"https://www.coherentmarketinsights.com/market-insight/monoclonal-antibody-therapeutics-market-2403","text":"valued at USD 331.81 Bn in 2026; CAGR of 12.9% (2026–2033)"},{"url":"https://www.biospace.com/monoclonal-antibody-therapeutics-market-size-to-reach-usd-919-06-billion-by-2033-propelled-by-pioneering-innovations-in-biopharmaceutical-engineering","text":"USD 233.19 billion in 2024; CAGR of 14.7% between 2024 and 2033"},{"url":"https://www.precedenceresearch.com/antibody-therapy-market","text":"valued at USD 973.6 billion in 2024; CAGR of 12% through 2034"},{"url":"https://www.persistencemarketresearch.com/market-research/biopharmaceutical-market.asp","text":"The global biopharmaceutical market size is valued at US$515.8 billion in 2025 and projected to reach US$910.7 billion; CAGR 8.5%."},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC4355252/","text":"Combined revenues from licensing and industry-supported research in all fields reaching well over $6 billion per year (AUTM 2012)."},{"url":"https://www.pharmexec.com/view/roundup-biotech-strategic-partnerships-exclusive-licensing-agreements","text":"Manifold Bio will receive an upfront fee of $55 million and eligibility for milestones valued upwards of $2 billion."}]}